Jardiance (Empagliflozin) in Special Populations: Transplant, HIV, Elderly, and Beyond

How Empagliflozin Works and Why Special Populations Matter

Empagliflozin is a selective inhibitor of sodium-glucose cotransporter 2 (SGLT2) in the proximal renal tubule. By blocking SGLT2, the drug prevents reabsorption of approximately 30 to 50% of filtered glucose, causing glycosuria that lowers plasma glucose independently of insulin secretion 1. This mechanism also promotes mild osmotic diuresis and natriuresis, which contributes to blood pressure reduction and the cardiorenal benefits observed in large outcome trials.

The EMPA-REG OUTCOME trial (N=7,020) demonstrated a 38% relative risk reduction in cardiovascular death among patients with type 2 diabetes and established cardiovascular disease randomized to empagliflozin versus placebo 2. EMPEROR-Reduced (N=3,730) later showed a 25% reduction in the composite of cardiovascular death or heart failure hospitalization in HFrEF patients regardless of diabetes status 3. These trials established empagliflozin as a first-line agent across cardiorenal disease. But their enrollment criteria largely excluded transplant recipients, people living with HIV, and other medically complex groups. That gap between trial populations and real-world prescribing is where the clinical challenge sits.

Kidney Transplant Recipients

Post-transplant diabetes mellitus (PTDM) affects 10 to 40% of kidney transplant recipients within the first year, driven by immunosuppressive agents like tacrolimus and corticosteroids 4. Managing hyperglycemia in this population is complicated by drug interactions, infection risk, and the need to preserve graft function.

Several single-center retrospective studies and small prospective trials have evaluated SGLT2 inhibitors in kidney transplant recipients. A 2021 systematic review of observational data found that SGLT2 inhibitors reduced HbA1c by 0.5 to 1.0% in transplant patients with PTDM, with stable estimated GFR over follow-up periods of 6 to 12 months 5. Empagliflozin does not undergo significant CYP3A4 metabolism, which minimizes pharmacokinetic interactions with calcineurin inhibitors like tacrolimus and cyclosporine 6. This is a meaningful advantage over some glucose-lowering agents that share hepatic metabolic pathways with immunosuppressants.

The primary safety signals in transplant patients mirror those in the general population: genital mycotic infections, volume depletion, and the theoretical risk of euglycemic diabetic ketoacidosis (DKA). Urinary tract infection rates may be slightly higher given baseline immunosuppression. The 2022 KDIGO guidelines acknowledge the potential cardiorenal benefits of SGLT2 inhibitors in transplant recipients but stop short of a formal recommendation, citing insufficient randomized controlled trial data 7.

Dr. Peter Rossing, head of complications research at the Steno Diabetes Center Copenhagen, stated: "SGLT2 inhibitors represent one of the most promising classes for managing post-transplant diabetes, but we need dedicated randomized trials in this population before we can make guideline-level recommendations."

Clinicians prescribing empagliflozin to transplant recipients should monitor tacrolimus trough levels at baseline and 2 to 4 weeks after initiation (despite low interaction risk), track eGFR monthly for the first 3 months, and counsel patients on genital hygiene to reduce mycotic infection incidence.

People Living With HIV

The intersection of HIV, metabolic disease, and cardiovascular risk creates a population with clear unmet need for cardiorenal-protective therapies. People living with HIV have a 1.5- to 2-fold higher risk of cardiovascular events compared to age-matched HIV-negative individuals, driven partly by chronic inflammation, antiretroviral-associated metabolic effects, and traditional risk factors 8.

Empagliflozin's pharmacokinetic profile is favorable in the context of antiretroviral therapy. The drug is primarily eliminated through UGT-mediated glucuronidation (UGT1A3, UGT1A8, UGT1A9) and renal excretion, with minimal CYP450 involvement 6. This means the major drug-drug interaction concerns with protease inhibitors (ritonavir, cobicistat) and NNRTIs (efavirenz, etravirine) that plague many diabetes medications are largely absent. A pharmacokinetic study of dapagliflozin (a related SGLT2 inhibitor) with antiretrovirals showed no clinically meaningful changes in exposure, and empagliflozin is expected to behave similarly given its comparable metabolic profile 9.

There are specific concerns worth noting. Tenofovir disoproxil fumarate (TDF) carries its own risk of proximal tubular dysfunction and Fanconi syndrome. Adding an SGLT2 inhibitor that acts on the proximal tubule raises theoretical questions about additive renal tubular stress. Patients on TDF-containing regimens should have baseline and periodic assessments of tubular function, including serum phosphate, urine glucose, and urine protein 10. Tenofovir alafenamide (TAF), the newer prodrug with reduced renal toxicity, is a safer backbone when combining with empagliflozin.

The REPRIEVE trial (N=7,769), which studied pitavastatin for primary cardiovascular prevention in people with HIV, established that this population benefits from proactive cardiometabolic intervention 11. The FDA label for empagliflozin does not specifically address HIV. No randomized trial has been completed exclusively in people with HIV, though several are ongoing or in planning stages. In practice, many HIV-specialized endocrinologists now prescribe SGLT2 inhibitors to their patients with type 2 diabetes or heart failure on a case-by-case basis.

Older Adults (Age 65 and Above)

Empagliflozin does not require dose adjustment based on age alone. However, the risk profile shifts meaningfully in patients over 75.

A prespecified subgroup analysis of EMPA-REG OUTCOME found consistent cardiovascular benefit across age groups, including patients aged 65 and older 2. The EMPEROR-Preserved trial (N=5,988) demonstrated a 21% reduction in the composite of cardiovascular death or heart failure hospitalization in HFpEF, a condition that disproportionately affects older adults 12. These data support use in the elderly for both glycemic and cardiovascular indications.

The key safety concern is volume depletion. Older adults are more likely to be on concurrent diuretics (loop or thiazide), have reduced thirst perception, and have lower baseline intravascular volume. The prescribing information reports hypotension-related adverse events in 1.3% of empagliflozin-treated patients versus 0.7% on placebo, with higher rates in patients aged 75 and above 13.

Falls are a downstream consequence. A 2023 pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) found that SGLT2 inhibitors were associated with a modest signal for fall-related injuries in patients over 80, likely mediated by orthostatic hypotension 14. Practical steps to reduce this risk include starting at the 10 mg dose, holding concurrent thiazide diuretics or reducing their dose at initiation, checking orthostatic blood pressure at the 2-week follow-up, and ensuring adequate fluid intake (target 1.5 to 2 liters daily unless fluid-restricted for heart failure).

The American Geriatrics Society Beers Criteria do not list SGLT2 inhibitors as potentially inappropriate medications for older adults, reflecting their overall favorable safety profile in this population.

Chronic Kidney Disease and the Updated Renal Threshold

The renal threshold for empagliflozin initiation has shifted substantially since initial approval. The original label restricted use to eGFR ≥45 mL/min/1.73 m². Following results from EMPA-KIDNEY (N=6,609), which showed a 28% reduction in the composite of kidney disease progression or cardiovascular death across a broad eGFR range 15, the FDA updated the label to permit initiation at eGFR ≥20 mL/min/1.73 m² for heart failure and CKD indications.

The 2024 KDIGO CKD guideline recommends SGLT2 inhibitors as first-line therapy for patients with CKD and eGFR ≥20, with or without diabetes 7. Dr. Vlado Perkovic, co-chair of the EMPA-KIDNEY steering committee, noted: "The data are clear that SGLT2 inhibitors protect the kidney across a much wider range of renal function than we originally thought, and the risk-benefit ratio remains favorable even in advanced CKD."

At very low eGFR values (20 to 30 mL/min/1.73 m²), the glycemic effect of empagliflozin is minimal because less glucose is filtered. The cardiorenal benefits, however, appear to be independent of glucose lowering and instead relate to tubuloglomerular feedback modulation, reduced intraglomerular pressure, and anti-inflammatory effects on the tubulointerstitium 16. Patients in this eGFR range should be monitored for hyperkalemia (particularly if on RAAS inhibitors), volume status, and the expected initial eGFR dip of 3 to 5 mL/min/1.73 m² that typically stabilizes within 4 to 8 weeks.

Hepatic Impairment

Empagliflozin undergoes hepatic glucuronidation, but pharmacokinetic studies show no clinically significant changes in drug exposure in patients with mild (Child-Pugh A) or moderate (Child-Pugh B) hepatic impairment 6. No dose adjustment is needed for these patients.

Data in severe hepatic impairment (Child-Pugh C) are limited. The FDA label advises against use in this population due to insufficient evidence rather than a documented safety signal 13. Patients with decompensated cirrhosis present additional challenges: they are prone to hypovolemia from ascites and diuretic use, which could amplify the volume-depleting effects of SGLT2 inhibition. Empagliflozin has shown preliminary interest in nonalcoholic steatohepatitis (NASH/MASLD) trials due to its effects on body weight and hepatic fat, but current evidence from the E-LIFT trial (N=50) is limited to reductions in liver fat on MRI-proton density fat fraction without histological endpoints 17.

Pregnancy and Lactation

Empagliflozin is not recommended during pregnancy. Animal studies in rats and rabbits demonstrated adverse effects on renal development (renal pelvic and tubular dilation) when empagliflozin was administered during the period corresponding to the second and third trimesters of human gestation 13. No controlled human studies exist.

The mechanism itself poses a concern. SGLT2 is expressed in the fetal kidney, and inhibiting glucose reabsorption during nephrogenesis could impair normal renal development. Women of childbearing potential should use effective contraception while taking empagliflozin, and the drug should be discontinued as soon as pregnancy is recognized. Insulin remains the standard of care for glucose management during pregnancy.

Empagliflozin was detected in the milk of lactating rats, but human lactation data are not available. The prescribing information recommends against breastfeeding during treatment 13.

Type 1 Diabetes: An Off-Label Consideration

Empagliflozin is not FDA-approved for type 1 diabetes. The EASE program (EASE-2, N=730; EASE-3, N=977) studied empagliflozin as an adjunct to insulin in T1D and found statistically significant HbA1c reductions of 0.28% with the 2.5 mg dose and 0.54% with the 25 mg dose versus placebo 18. Body weight decreased by approximately 1.8 to 3.0 kg. The 2.5 mg dose (lower than any approved dose for T2D) showed a DKA rate similar to placebo, while the 25 mg dose carried a DKA rate of 4.3% versus 1.2% with placebo.

The European Medicines Agency issued a class warning for SGLT2 inhibitors in T1D, and the FDA has not granted an indication. Any off-label use in T1D requires careful patient selection: candidates must have a BMI of 27 kg/m² or higher, C-peptide confirming some residual beta-cell function, willingness to monitor ketones with home blood beta-hydroxybutyrate meters, and education on sick-day rules including drug discontinuation during illness, fasting, or perioperative periods.

Perioperative Considerations Across All Special Populations

The American College of Surgery and the American Society of Anesthesiologists recommend holding SGLT2 inhibitors for at least 3 to 4 days before elective surgery due to the risk of euglycemic DKA 19. This guidance applies uniformly across special populations but carries added weight in transplant recipients (who may undergo graft-related procedures), older adults (who undergo orthopedic surgeries at higher rates), and patients with CKD (whose acid-base buffering capacity may be reduced).

Empagliflozin has a plasma half-life of approximately 12.4 hours, but SGLT2 inhibition persists for 2 to 3 days after the last dose due to the slow off-rate from the transporter. Patients should carry medical identification noting SGLT2 inhibitor use, and perioperative teams should check point-of-care blood ketones if the patient presents with metabolic acidosis and a normal or near-normal blood glucose (a classic euglycemic DKA pattern).

Restart empagliflozin only after the patient is eating normally and has no active ketonemia (blood beta-hydroxybutyrate <0.6 mmol/L).